Cordis IVC filters are medical devices placed in the inferior vena cava with the intention of catching blood clots and stopping them from traveling to the heart or lungs. Cordis sells two brands of IVC filters—CordisOptEase and CordisTrapEase—that have been linked to reported adverse events and injuries.
Cordis TrapEase Filter
The FDA cleared the Cordis TrapEase IVC filter through the 510(k) process as a permanent device on July 7, 2000. Unlike the Cordis OptEase, the TrapEase does not have a retrievable sign. Since its release to the market, scientific literature has questioned the safety and efficacy of the TrapEase. In particular, the design of the TrapEase may lead to an increased risk of a blood clot formation around the filter, the very injury the filter existed to prevent. Further studies raise concern about other TrapEase complications. Including the ability to remove the TrapEase once implanted and the risk of fracturing.
